PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SM ...
Abstract
Authors
A. Tfayli F. Elias F. Farhat R. Slim Z. Hallal L. Maatouk A. Ibrahim I. Anan